Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Huang, Yan ^a   Li, Lin Zi ^a   Zhang, Chris Z ^a   Yi, Chun ^a   Liu, Li Li ^a   Zhou, Xuan ^a   Xie, Guo Bing ^a   Cai, Mu Yan ^a   Li, Yan ^a   Yun, Jing Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

AZGP1; Hepatocellular carcinoma; Metastasis; Prognosis; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2 GLYCOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR RECURRENCE;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEMINAL PLASMA PROTEINS; TISSUE ARRAY ANALYSIS;

EID: 84861332242     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-106     Document Type: Article

References (34)

1. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009, 8:124-133.
2. Zheng L, Liang P, Li J, Huang XB, Wang WW, Wang L, Feng H. Expression of BC047440 protein in hepatocellular carcinoma and its relationship to prognosis. Chin J Cancer 2010, 29:931-936. 10.5732/cjc.010.10272, 20979692.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063. 10.1002/hep.22580, 19003900.
4. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011, 9:171. 10.1186/1479-5876-9-171, 3213217, 21985599.
5. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2011, 2:e150. 10.1038/cddis.2011.34, 3122065, 21525937.
6. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 2010, 31:179-193. 10.1016/j.mam.2010.02.007, 20176048.
7. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012, 3:e259. 10.1038/cddis.2011.136, 3270270, 22258409.
8. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res 2008, 6:892-906. 10.1158/1541-7786.MCR-07-2195, 18567794.
9. Zorin NA, Zorina VN, Zorina RM. Role of proteins of the macroglobulin family in regulation of tumor growth. Ontogenez 2006, 37:12-19.
10. Zorin NA, Zorina VN, Zorina RM. The role of macroglobulin family proteins in the regulation of inflammation. Biomed Khim 2006, 52:229-238.
11. Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H, Eimoto T. Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 1991, 39:1221-1226. 10.1177/39.9.1918940, 1918940.
12. He N, Brysk H, Tyring SK, Ohkubo I, Brysk MM. Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression. J Cell Biochem Suppl 2001, 36(Suppl):162-169.
13. Kong B, Michalski CW, Hong X, Valkovskaya N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H, Kleeff J. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-beta-mediated ERK signaling. Oncogene 2010, 29:5146-5158. 10.1038/onc.2010.258, 20581862.
14. Albertus DL, Seder CW, Chen G, Wang X, Hartojo W, Lin L, Silvers A, Thomas DG, Giordano TJ, Chang AC, et al. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol 2008, 3:1236-1244. 10.1097/JTO.0b013e318189f5ec, 18978557.
15. Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-Otin C. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 1993, 29A:1256-1260.
16. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001, 7:846-853.
17. Brysk MM, Lei G, Adler-Storthz K, Chen Z, Brysk H, Tyring SK, Arany I. Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Lett 1999, 137:117-120. 10.1016/S0304-3835(98)00347-4, 10376801.
18. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006, 98:1420-1424. 10.1093/jnci/djj378, 17018789.
19. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004, 101:811-816. 10.1073/pnas.0304146101, 321763, 14711987.
20. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
21. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9, 9351551.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
23. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645. 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B, 11135226.
24. Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 2011, 9:5. 10.1186/1479-5876-9-5, 3022728, 21205329.
25. Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergun S. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5:4296-4304. 10.1002/pmic.200402005, 16196100.
26. Abdul-Rahman PS, Lim BK, Hashim OH. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis 2007, 28:1989-1996. 10.1002/elps.200600629, 17503403.
27. Lei G, Arany I, Selvanayagam P, Rajaraman S, Ram S, Brysk H, Tyring SK, Brysk MM. Detection and cloning of epidermal zinc-alpha 2-glycoprotein cDNA and expression in normal human skin and in tumors. J Cell Biochem 1997, 67:216-222. 10.1002/(SICI)1097-4644(19971101)67:2<216::AID-JCB6>3.0.CO;2-#, 9328826.
28. Mazoujian G. Apocrine carcinoma of the breast. Am J Clin Pathol 1990, 94:485-486.
29. Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006, 66:1037-1043. 10.1002/pros.20405, 16598739.
30. Gagnon S, Tetu B, Dube JY, Tremblay RR. Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases. Am J Pathol 1990, 136:1147-1152. 1877423, 2349965.
31. Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP, Caldefie-Chezet F. Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?. Anticancer Res 2010, 30:2919-2925.
32. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 2004, 101:2500-2505. 10.1073/pnas.0308647100, 356979, 14983038.
33. Russell ST, Tisdale MJ. Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins Leukot Essent Fatty Acids 2005, 72:409-414. 10.1016/j.plefa.2005.03.002, 15899583.
34. Lapointe J, Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, et al. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature. Am J Surg Pathol 2008, 32:205-209. 10.1097/PAS.0b013e318124a865, 18223322.